Literature DB >> 21212418

Ron kinase transphosphorylation sustains MET oncogene addiction.

Silvia Benvenuti1, Luca Lazzari, Addolorata Arnesano, Giulia Li Chiavi, Alessandra Gentile, Paolo M Comoglio.   

Abstract

Receptors for the scatter factors HGF and MSP that are encoded by the MET and RON oncogenes are key players in invasive growth. Receptor cross-talk between Met and Ron occurs. Amplification of the MET oncogene results in kinase activation, deregulated expression of an invasive growth phenotype, and addiction to MET oncogene signaling (i.e., dependency on sustained Met signaling for survival and proliferation). Here we show that cancer cells addicted to MET also display constitutive activation of the Ron kinase. In human cancer cell lines coexpressing the 2 oncogenes, Ron is specifically transphosphorylated by activated Met. In contrast, Ron phosphorylation is not triggered in cells harboring constitutively active kinase receptors other than Met, including Egfr or Her2. Furthermore, Ron phosphorylation is suppressed by Met-specific kinase inhibitors (PHA-665752 or JNJ-38877605). Last, Ron phosphorylation is quenched by reducing cell surface expression of Met proteins by antibody-induced shedding. In MET-addicted cancer cells, short hairpin RNA-mediated silencing of RON expression resulted in decreased proliferation and clonogenic activity in vitro and tumorigenicity in vivo. Our findings establish that oncogene addiction to MET involves Ron transactivation, pointing to Ron kinase as a target for combinatorial cancer therapy. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212418     DOI: 10.1158/0008-5472.CAN-10-2100

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

2.  The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome.

Authors:  Peter T Yu; Michele Babicky; Dawn Jaquish; Randy French; Karly Marayuma; Evangeline Mose; Sherry Niessen; Heather Hoover; David Shields; David Cheresh; Benjamin F Cravatt; Andrew M Lowy
Journal:  Int J Cancer       Date:  2012-03-08       Impact factor: 7.396

3.  An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics.

Authors:  Silvia Benvenuti; Alessandra Gentile; Luca Lazzari; Addolorata Arnesano; Livio Trusolino; Paolo M Comoglio
Journal:  Mol Oncol       Date:  2013-12-18       Impact factor: 6.603

4.  IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration.

Authors:  Dawn V Jaquish; Peter T Yu; David J Shields; Randall P French; Karly P Maruyama; Sherry Niessen; Heather Hoover; David A Cheresh; Ben Cravatt; Andrew M Lowy
Journal:  Carcinogenesis       Date:  2011-05-11       Impact factor: 4.944

Review 5.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

6.  The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Chem Rev       Date:  2018-12-27       Impact factor: 60.622

7.  Identification of a RON tyrosine kinase receptor binding peptide using phage display technique and computational modeling of its binding mode.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Mol Model       Date:  2017-08-19       Impact factor: 1.810

8.  Receptor tyrosine kinase recepteur d'origine nantais as predictive marker for aggressive prostate cancer in African Americans.

Authors:  Roble G Bedolla; Dimpy P Shah; Shih-Bo Huang; Robert L Reddick; Rita Ghosh; Addanki P Kumar
Journal:  Mol Carcinog       Date:  2019-03-11       Impact factor: 4.784

Review 9.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

Review 10.  The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies.

Authors:  Chang Moo Kang; Michele L Babicky; Andrew M Lowy
Journal:  Pancreas       Date:  2014-03       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.